Lobbying Relationship

Client

AstraZeneca Pharmaceuticals LP

More records

Lobbying firm

Todd Strategy Group

More records

  • Drug Pricing. General issues related to rare disease and orphan drugs. General issues related to diagnostics for patients with rare diseases. Items related to the Administrations Cancer Moonshot. Prescription Drug User Fee Act (PDUFA).
  • General issues related to patient access to rare disease therapies, Part B and Part D drugs. Issues related to home infusion for Part B patients. Issues related to home infusion for Part B patients.
  • Issues related to the 340B drug discount program.

Duration: to

General Issues: Pharmacy, Health Issues, Medicare/Medicaid

Spending: about $1,040,000 (But it's complicated. Here's why.)

Agencies lobbied since 2019: House of Representatives, U.S. Senate, Food & Drug Administration (FDA), Health & Human Services - Dept of (HHS)

Bills mentioned

H.R.5376: Inflation Reduction Act of 2022

Sponsor: John Yarmuth (D-Ky.)

H.R.3684: Infrastructure Investment and Jobs Act

Sponsor: Peter A. DeFazio (D-Ore.)

Show All Mentioned Bills

Lobbyists

Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.

Lobbyist Covered positions?
Daniel Todd Senior Health Counsel, Senate Finance Committee; Special Assistant, Office of Admin. Ct. - Medicare & Medicaid Senior Health Counsel, Senate Finance Committee; Special Assistant, Office of Admin. Ctr. - Medicare & Medicaid
Paul Edattel Chief Health Counsel, House Energy & Commerce Committee; Policy Assistant, Office of the Speaker; Professional Staff Member for the Majority at the House Energy & Commerce Committee; Legislative Assistant & Legislative Director, Rep. John Shadegg
Jeff Lucas Health Policy Advisor, Senator Bill Cassidy; Legislative Assistant/Sr. Legislative Assistant/Legislative Correspondent, Representative Larry Bucshon
Taylor Sexton Advisor to the Assistant Secretary for Preparedness & Response, HHS; Advisor to the Assistant Secretary of Legislation, HHS; Health Care Policy Fellow, Representative Michael Burgess

Disclosures Filed

Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.

Termination
Q1 Report
Q4 Report
Q3 Report
Q2 Report
Q1 Report
Q4 Report
Q3 Report
Q2 Report
Q1 Report
Q4 Report
Q3 Report
Q2 Report
Q1 Report
Q4 Report
Q3 Report
Q2 Report
Q1 Report
Registration

Source: Clerk of the U.S. House of Representatives and Secretary of the Senate

Close Comment Creative Commons Donate Email Facebook Mobile Phone Podcast Print Google News logo Google_NewsInitiative_Lockup_FullColor RSS Search Search Twitter WhatsApp Resolving differences Check Building Arrow right Info circle Oops OOPS Pencil File text Bars Search Close Cogs Filter Compare Revolving Door Info card Activity Member menu Globe Document External link Quote News Calendar No Vote
Current site Current page